Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH5 | P11766 | 1/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | POLB | P06746 | 5/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL248012 | 0.89 | ADH5 (0.80) | ADH5CYP2C19MAPTPOLBTP53 | |
| SCHEMBL244680 | 0.86 | ADH5 (0.78) | ADH5CYP2C19MAPTPOLBTP53 | |
| N6022 SCHEMBL29502874 | 0.86 | ADH5 (1.00) | ADH5CYP2C19MAPTPOLBTP53 | |
| N6022 SCHEMBL244480 | 0.86 | ADH5 (1.00) | ADH5CYP2C19MAPTPOLBTP53 | |
| SCHEMBL244176 | 0.86 | ADH5 (0.74) | ADH5CYP2C19MAPTPOLBTP53 | |
| SCHEMBL245660 | 0.84 | ADH5 (0.71) | ADH5CYP2C19MAPTPOLBTP53 | |
| SCHEMBL243641 | 0.84 | ADH5 (0.75) | ADH5CYP2C19MAPTPOLBTP53 | |
| SCHEMBL244620 | 0.84 | ADH5 (0.72) | ADH5CYP2C19MAPTPOLBTP53 | |
| SCHEMBL243935 | 0.83 | ADH5 (0.70) | ADH5CYP2C19MAPTPOLBTP53 | |
| SCHEMBL1835725 | 0.83 | ADH5 (0.70) | ADH5CYP2C19MAPTPOLBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9814700-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents | NIVALIS THERAPEUTICS, INC. (US) | 2017-11-14 | — | — | US | claimed |
| US-20170049750-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | LAUREL THERAPEUTICS LTD. (CN) | 2017-02-23 | — | — | US | claimed |
| US-9498466-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents | NIVALIS THERAPEUTICS, INC. (US) | 2016-11-22 | — | — | US | claimed |
| EP-2318006-B1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | NIVALIS THERAPEUTICS INC (US) | 2016-10-12 | — | — | EP | claimed |
| EP-3069721-A1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | Nivalis Therapeutics, Inc. (US) | 2016-09-21 | — | — | EP | claimed |
| EP-2315591-B1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | NIVALIS THERAPEUTICS INC (US) | 2016-03-16 | — | — | EP | claimed |
| US-20160045477-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | LAUREL THERAPEUTICS LTD. (CN) | 2016-02-18 | — | — | US | claimed |
| US-9180119-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents | NIVALIS THERAPEUTICS, INC. (US) | 2015-11-10 | — | — | US | claimed |
| US-20150126570-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | LAUREL THERAPEUTICS LTD. (CN) | 2015-05-07 | — | — | US | claimed |
| US-8957105-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents | N30 PHARMACEUTICALS, INC. (US) | 2015-02-17 | — | — | US | claimed |
| US-20140155447-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | N30 PHARMACEUTICALS, INC. (US) | 2014-06-05 | — | — | US | claimed |
| US-8673961-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents | N30 PHARMACEUTICALS, INC. (US) | 2014-03-18 | — | — | US | claimed |
| JP-2012500219-A | — | — | 2012-01-05 | — | — | JP | claimed |
| JP-2012500216-A | — | — | 2012-01-05 | — | — | JP | claimed |
| US-20110144180-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | N30 PHARMACEUTICALS, LLC (US) | 2011-06-16 | — | — | US | claimed |
| US-20110144110-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | N30 PHARMACEUTICALS, LLC (US) | 2011-06-16 | — | — | US | claimed |
| EP-2318006-A1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | N30 Pharmaceuticals, LLC (US) | 2011-05-11 | — | — | EP | claimed |
| EP-2315591-A1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | N30 Pharmaceuticals, LLC (US) | 2011-05-04 | — | — | EP | claimed |
| WO-2010019910-A1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | N30 PHARMACEUTICALS, LLC (US) | 2010-02-18 | — | — | WO | claimed |
| WO-2010019903-A1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | N30 PHARMACEUTICALS, LLC (US) | 2010-02-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160045477-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | GSR, DHFR, GRHPR | ADH5 82/4885CYP2C19 548/4885MAPT 3482/4885 |
| US-20170049750-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | GSR, DHFR, GRHPR | ADH5 82/4885CYP2C19 548/4885MAPT 3482/4885 |
| US-20140155447-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | GSR, DHFR, GRHPR | ADH5 82/4885CYP2C19 548/4885MAPT 3482/4885 |
| US-20150126570-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | GSR, DHFR, GRHPR | ADH5 82/4885CYP2C19 548/4885MAPT 3482/4885 |
| US-20110144180-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | GSR, DHFR, GRHPR | ADH5 82/4885CYP2C19 548/4885MAPT 3482/4885 |
| US-20110144110-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | GSR, DHFR, GRHPR | ADH5 82/4885CYP2C19 548/4885MAPT 3482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.